
SouthernBiotech



Hamster Anti-Mouse CD152

Cat. No.	Format	Size
1790-01	Purified (UNLB)	0.5 mg
1790-02	Fluorescein (FITC)	0.5 mg
1790-08	Biotin (BIOT)	0.5 mg
1790-09	R-phycoerythrin (PE)	0.1 mg
1790-14	Low Endotoxin, Azide-Free (LE/AF)	0.5 mg



FLISA plate was coated with mouse CD152/CTLA-4 and purified/unlabeled Rat $lgG1\kappa$. CTLA-4 and purified immunoglobulin were detected with serially diluted Hamster Anti-Mouse CD152-PE (SB Cat. No. 1790-09).

Overview

Clone 1B8

Isotype Hamster (Armenian) IgG₁

Immunogen Extracellular portion of murine CTLA-4 fused to a murine IgG_{2a}

Specificity Mouse CD152; Mr 33-37 kDa

Alternate Name(s) CTLA-4, cytotoxic T-lymphocyte protein 4

Description

The lymphocyte surface antigen CD152, also known as CTLA-4, is related to the costimulatory molecule CD28 and both molecules share common B7 family counter-receptors. However CD152 is thought to be a negative regulator of T cell activation and may play a role in apoptotic control of T cells. CD152 is relatively conserved among humans, mice and chickens.

Applications

ELISA – Quality tested ² FLISA – Quality tested FC – Reported literature ³⁻¹¹ Stim – Reported in literature ¹

Working Dilutions

ELISA	BIOT conjugate	1:5,000 - 1:10,000
FLISA	FITC conjugate PE conjugate	1:100 − 1:400 ≤ 1 μg/mL
Flow Cytometry	FITC and BIOT conjugates PE conjugate For flow cytometry, the suggested use of these reagents is in a final	$\leq 3~\mu g/10^6$ cells $\leq 0.3~\mu g/10^6$ cells al volume of 100 μL
Other Applications	Since applications vary, you should determine the optimum working dilution for the product that is appropriate for your specific need.	

For Research Use Only. Not for Diagnostic or Therapeutic Use.

Email: info@southernbiotech.com • Website: www.southernbiotech.com

Handling and Storage

- The purified (UNLB) antibody is supplied as 0.5 mg of purified immunoglobulin in 1.0 mL of borate buffered saline, pH 8.2. No
 preservatives or amine-containing buffer salts added. Store at 2-8°C.
- The fluorescein (FITC) conjugate is supplied as 0.5 mg in 1.0 mL of PBS/NaN₃. Store at 2-8°C.
- The biotin (BIOT) conjugate is supplied as 0.5 mg in 1.0 mL of PBS/NaN₃. Store at 2-8°C.
- The R-phycoerythrin (PE) conjugate is supplied as 0.1 mg in 1.0 mL of PBS/NaN₃ and a stabilizing agent. Store at 2-8°C. Do not freeze!
- The low endotoxin, azide-free (LE/AF) antibody is supplied as 0.5 mg purified immunoglobulin in 1.0 mL of PBS. Contains no preservative; handle under aseptic conditions. Store at 2-8°C or aliquot into smaller volumes and store at -20°C. Avoid multiple freeze / thaw cycles.
- Protect fluorochrome-conjugated forms from light. Reagents are stable for the period shown on the label if stored as directed.

Warning

Some reagents contain sodium azide. Please refer to product specific SDS.

References

- 1. Walunas TL, Lenschow DJ, Bakker CY, Linsley PS, Freeman GJ, Green JM, et al. CTLA-4 can function as a negative regulator of T cell activation. Immunity. 1994;1:405-13. (Immunogen, Stim)
- Kimura F, Gotoh M, Tanaka T, Luo Z, Miyazaki J, Uede T, et al. Locally expressed CTLA4-Ig in a pancreatic beta-cell line suppresses accelerated graft rejection response induced by donor-specific transfusion. Diabetologia. 2002;45:831-40. (ELISA)
- Ben-David H, Sela M, Mozes E. Down-regulation of myasthenogenic T cell responses by a dual altered peptide ligand via CD4*CD25*-regulated events leading to apoptosis. Proc Natl Acad Sci USA. 2005;102:2028-33. (FC)
- Sharabi A, Mozes E. The suppression of murine lupus by a tolerogenic peptide involves Foxp3-expressing CD8 cells that are required for the optimal induction and function of Foxp3-expressing CD4 cells. J Immunol. 2008;181:3243-51. (FC)
- Laronne-Bar-On A, Zipori D, Haran-Ghera N. Increased regulatory versus effector T cell development is associated with thymus atrophy in mouse models of multiple myeloma. J Immunol. 2008;181:3714-24. (FC)
- 6. Barnes MJ, Krebs P, Harris N, Eidenschenk C, Gonzalez-Quintal R, Arnold CN, et al. Commitment to the regulatory T cell lineage requires CARMA1 in the thymus but not in the periphery. PloS Biol. 2009;7(3):e1000051. (FC)
- 7. Scalapino KJ, Daikh DI. Suppression of glomerulonephritis in NZB/NZW lupus prone mice by adoptive transfer of ex vivo expanded regulatory T cells. PLoS One. 2009;4(6):e6031. (FC)
- 8. Wafula PO, Teles A, Schumacher A, Pohl K, Yagita H, Volk H, et al. PD-1 but not CTLA-4 blockage abrogates the protective effect of regulatory T cells in a pregnancy murine model. Am J Reprod Immunol. 2009;62:283-92. (FC)
- Wang D, Zhou R, Yao Y, Zhu X, Yin Y, Zhao G, et al. Stimulation of α7 nicotinic acetylcholine receptor by nicotine increases suppressive capacity of naturally occurring CD4*CD25* regulatory T cells in mice in vitro. J Pharmacol Exp Ther. 2010;335:553-61. (FC)
- Zhang Y, Yao Y, Huang L, Dong N, Yu Y, Sheng Z. The potential effect and mechanism of high-mobility group box 1 protein on regulatory T cell-mediated immunosuppression. J Interferon Cytokine Res. 2011;31:249-57. (FC)
- 11. Duraiswamy J, Freeman GJ, Coukos G. Therapeutic PD-1 pathway blockade augments with other modalities of immunotherapy T-cell function to prevent immune decline in ovarian cancer. Cancer Res. 2013;73:6900-12. (FC)

TB1790 09-Oct-21

Email: info@southernbiotech.com • Website: www.southernbiotech.com